As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
10 Analysts have issued a Arbutus Biopharma Corporation forecast:
10 Analysts have issued a Arbutus Biopharma Corporation forecast:
| Jun '25 | 
    +/-
   
    %
   | ||
| Revenue | 15 15 | 
      
        
        53%
      
      
        
        53%
      
 | |
| Gross Profit | - - | 
    -
 | |
| EBITDA | -42 -42 | 
      
        
        48%
      
      
        
        48%
      
 | |
| EBIT (Operating Income) EBIT | -43 -43 | 
      
        
        48%
      
      
        
        48%
      
 | |
| Net Profit | -54 -54 | 
      
        
        30%
      
      
        
        30%
      
 | |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.
| Head office | Canada | 
| CEO | Lindsay Androski | 
| Employees | 44 | 
| Founded | 2005 | 
| Website | www.arbutusbio.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


